INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 15, 2004 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 89,463 | -- | 89,463 |
| Jul 24, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 89,463 | $9.49 | 89,813 |
| Feb 13, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,597 | $113.35 | 90,323 |
| Feb 13, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 257 | $113.35 | 91,920 |
| Feb 13, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,432 | $8.50 | 92,177 |
| Dec 15, 2003 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 92,308 | -- | 92,308 |
| Nov 05, 2015 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,047 | $567.63 | 92,982 |
| Aug 28, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 6,017 | $145.70 | 93,104 |
| Dec 13, 2013 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 95,000 | -- | 95,000 |
| Dec 18, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 95,079 | -- | 95,079 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.